HOME     ::     SERVICES     ::     ABOUT US     ::     NEWSROOM     ::     PIPELINE     ::     BIOSIMILARS     ::     CONTACT US


Our strategic partner's products are developed to the highest EMA standards and are tested to assure the active substance used in the comparability exercise is representative of the active substance present in the reference medicinal product.

INNOVATOR PRODUCT: originally developed and approved biologic having established manufacturing reproducibility, patient safety and efficacy, and marketability directed at one or more medical indications.

BIOSIMILARS / FOLLOW-ON PROTEIN PRODUCTS (FOPPs): subsequent versions of biologics that are independently developed and approved after a innovator has developed the original version.

BIOBETTER: products that may be structurally related to and directed at similar indications of an innovator product, but differ positively by one or more characteristics, efficacy/safety or a combination.




Biosimilar Source has a strategic alliance with a premier provider of marketable high- quality biologic APIs (biosimilars) for high unmet need indications, such as cancer, inflammation and autoimmunity. 

  • Abatacept (Orencia®)

  • Adalimumab (Humira®)

  • Alemtuzumab (Campath®, MabCampath® Campath-1H®)

  • Bevacizumab (Avastin®)

  • Cetuximab (Erbitux®)

  • Golimumab (Simponi®)

  • Infliximab (Remicade®)

  • Natalizumab (Tysabri®)

  • Omalizaumab (Xolair®)

  • Ofatumumab (Arzerra®)

  • Palivumab (Synagis®)

  • Panitumumab (Vectibix®)

  • Rituximab (Rituxan®, Mabthera®)

  • Tocilizumab (Actemra®, RoActemra®)

  • Trastuzumab (Hercpetin®)

  • Ustekinumab (Stelara®)




© Copyright 2010 Biosimilar Source and Biosimilar Source Partners. All rights reserved.
Biosimilar Source is a division of DNA Bridges, Inc.

15-Dec-2010 09:29:11 AM